Name
*
First Name
Last Name
Email
*
example@example.com
What best describes your title?
*
MD
RN/NP
PA
Professor
Industry
Other
How many patients do you currently see each month regarding chronic obstructive pulmonary disease (COPD)?
Less than 5
5-15
16-25
26 or more
N/A
How many years have you been in practice?
1. Which pairing of a COPD biologic with its mechanism of action is correct?
*
Dupilumab — blocks IL-4Rα, inhibiting both IL-4 and IL-13 signaling
Dupilumab — depletes eosinophils via IL-5Rα blockade
Itepekimab — blocks thymic stromal lymphopoietin (TSLP)
Mepolizumab — blocks the IL-4/IL-13 receptor complex
2. According to the current GOLD report, which of the following remains mandatory to confirm a diagnosis of COPD, despite the new emphasis on pre-bronchodilator screening?
*
Post-bronchodilator FEV1/FVC <0.7
Pre-bronchodilator FEV1/FVC <0.7 alone, without post-bronchodilator confirmation
Low-dose CT evidence of emphysema alone
A CAT score >15 alone
3. Based on recent phase 3 data in eosinophilic COPD, which biologic has NOT demonstrated clear clinical benefit?
*
Benralizumab
Dupilumab
Mepolizumab (benefit limited mainly to exacerbation reduction)
All of the above have shown robust, consistent benefit
4. A patient with COPD, chronic bronchitis, and 2 moderate exacerbations in the past year despite adherent triple inhaled therapy has a blood eosinophil count of 320 cells/µL confirmed on two occasions. Which statement best reflects current practice for biologic selection?
*
Dupilumab is a reasonable first-line biologic option given its superior efficacy across exacerbation, lung function, and symptom domains in this phenotype
Biologic therapy should be deferred until FEV1 declines below 30% predicted
Any anti-IL-5 biologic should be used regardless of eosinophil count or bronchitis phenotype
Biologic therapy is contraindicated because the patient is on triple inhaled therapy
Please rate the extent to which this activity met the following objectives:
Rows
Poor
Fair
Good
Very Good
Excellent
Explore the molecular targets and mechanisms of action for new and emerging biologic therapeutics for COPD in order to link the mechanism of action to patient needs
Examine the updated GOLD guidelines in order to diagnosis COPD accurately and in a timely manner
Evaluate the latest evidence for new and emerging biologic therapeutics for COPD in order to update and maintain optimal treatment plans once approved
Develop strategies to prepare to select and sequence new and emerging COPD therapeutics for individual patients in order to improve patient outcomes
Please provide feedback regarding your experience with this activity:
Rows
Poor
Fair
Good
Very Good
Excellent
Overall
Content
Usefulness
Do you feel this activity was fair balanced and free of commercial bias?
Yes
No
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Yes
No
N/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
I gained new strategies/skills/information that my team can apply to practice
I plan to implement new strategies/skills/information in my practice
I will be more competent in my team’s management of patient care
I will improve my communication with the healthcare team
What factors beyond clinical care that affect the health of your patients does your team experience?
Date
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
Course Title
Credits
Submit
Should be Empty: